Clinical trial KILT
A randomized non-comparative Phase II Study of Lacutamab with Gemox versus Gemox alone in relapsed/refractory Patients with Peripheral T-cell Lymphoma
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial open for recruitment |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | Lysarc |
| EudraCT Identifier | 2020-003735-16 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04984837 |
| Inclusion criteria | - KIR3DL2-positive- Relapsed/refractory PTCL after at least one previous line, with a maximum of 2 prior lines of systemic therapies- ECOG performance status 0 to 3 prior to prephase treatment, and 0 to 2 prior randomization |
| Last update |